Algigenomics and Glujin Therapeutics Sign MOU for Next-Generation AAV-Based RNA Gene Therapies

On the 23rd, Algigenomics, a company specializing in the development of ribonucleic acid (RNA)-based gene therapies, and Glujin Therapeutics, a company specializing in the development of adeno-associated virus (AAV) vectors, announced that they had signed a “strategic business agreement (MOU) for the development of next-generation AAV-based precision-guided RNA gene therapies.”

This collaboration aims to combine Algigenomics’ proprietary RNA replacement-enzyme-based precision editing platform with Glujin Therapeutics’ AI-driven discovery technology for next-generation AAV vectors, in order to maximize target cell selectivity and delivery efficiency, and to jointly build next-generation gene therapy solutions focused on patient convenience.

AAV vector technology is already a commercially validated platform. In fact, more than 50% of gene therapies approved by the U.S. Food and Drug Administration (FDA) use AAV vectors, and according to a global market research firm, the AAV gene therapy market is expected to grow at an average annual rate of 26% to reach 23.5 billion dollars by 2034.

However, to further expand AAV technology, there are technical challenges such as increasing the size of the transgene, enhancing tissue specificity, minimizing immune responses, and achieving low-dose, high-efficiency delivery. The two companies plan to focus on developing next-generation gene therapies that overcome these limitations through AI-based vector design and improve access to RNA-based precision therapies. They also intend to secure a platform that can be expanded to a wide range of intractable diseases, including genetic disorders and central nervous system diseases.

Lee Sungwook, CEO of Algigenomics, said, “Through our collaboration with Glujin Therapeutics, we will further strengthen the therapeutic competitiveness and disease expandability of our RNA platform, and we will strive to provide patients with greater convenience and access to treatment.”

Lee Moonsu, CEO of Glujin Therapeutics, said, “Through our collaboration with Algigenomics, we will demonstrate the value of Glujin Therapeutics’ data-driven precision-guided AAV platform, and based on the synergy between the two companies, we will further solidify our position in the gene therapy market.”